Researchers analyzed data on gliblastoma multiforme patients nationwide diagnosed between 1991 and 2007 in the Surveillance, Epidemiology and End Results Medicare database. They found 15.8 percent of patients were readmitted within 30 days. The median survival time for readmitted patients was six months, compared to 7.6 months for nonreadmitted patients. Readmission increased mortality rates by 30 percent.
Researchers suggest future studies are needed to help reduce readmissions and evaluate the impact readmissions have on patient outcomes.
More Articles on Readmissions:
Study: 15% of Avoidable Readmissions Linked to End-of-Life Care Issues
Readmission Rates Constant for Different Prostate Surgery Techniques
SSI Most Powerful Predictor of Surgical Readmission
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.